Jeffrey Ubben
ValueAct Holdings
Jeffrey Ubben Dentsply Sirona Inc stake
total: 107
ValueAct Holdings XRAY trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2018 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2018 Q4
According to 2026 Q2 report, Jeffrey Ubben doesn't hold any Dentsply Sirona Inc (XRAY) shares. To date, the estimated cost basis is nearly $37.74 for "buy" trades and estimated average "sell" price is $37.74. ValueAct Holdings first purchased XRAY in 2018 Q3, initially acquiring about 2.20M shares. Since the initial investment in Dentsply Sirona Inc (XRAY), ValueAct Holdings has made 1 more transaction.
When did Jeffrey Ubben sell Dentsply Sirona Inc (XRAY)?
Jeffrey Ubben sold off the entire Dentsply Sirona Inc (XRAY) position in 2018 Q4.
When did Jeffrey Ubben buy Dentsply Sirona Inc (XRAY)?
Jeffrey Ubben first invested in Dentsply Sirona Inc (XRAY) in 2018 Q3 at the reported quarter-end price of $37.74 per share.
What's the cost basis of ValueAct Holdings's XRAY stake?
The estimated cost basis for Dentsply Sirona Inc (XRAY) stake is around $37.74 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $37.74
- Weighted AVG sell price:
- $37.74
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.